Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Testing clinical therapeutic angiogenesis using basic fibroblast growth factor (FGF-2).

Ronnier J Aviles1, Brian H Annex, Robert J Lederman

  • 1The Cardiovascular Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Building 10, Room 2C713, MSC 1538, Bethesda, MD 20892-1538, USA.

British Journal of Pharmacology
|October 10, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Vascular Endothelial Growth Factor Receptors 1 and 3 Mediate Placental Trophoblast Leptin Production in Preeclampsia, Inducing Vascular Dysfunction.

Arteriosclerosis, thrombosis, and vascular biology·2026
Same author

Mitral Valve Leaflet Modification: A Working Group Position Statement on Best Practices and Step-by-Step Guide.

JACC. Cardiovascular interventions·2026
Same author

UNICORN During Transcatheter Aortic Valve Replacement in Native and Bioprosthetic Aortic Valves: A Multicenter Study.

JACC. Cardiovascular interventions·2026
Same author

Failure Mechanisms in Off-Label Electrosurgery Devices for BASILICA, LAMPOON, and SESAME.

JACC. Cardiovascular interventions·2026
Same author

Aortic Valve Leaflet Modification: A Working Group Position Statement on Best Practices and Step-by-Step Guide.

JACC. Cardiovascular interventions·2026
Same author

Current Evidence, Emerging Evidence, and Decision-Making: An Algorithm for Leaflet Modification Procedures.

JACC. Cardiovascular interventions·2026

Therapeutic angiogenesis using basic fibroblast growth factor (FGF-2) shows promise for cardiovascular diseases. While some trials demonstrate proof of concept, efficacy varies, necessitating optimized clinical trial designs for FGF-2 development.

Area of Science:

  • Biomedical Engineering
  • Cardiovascular Research
  • Regenerative Medicine

Background:

  • Therapeutic angiogenesis aims to improve blood flow by stimulating new blood vessel growth.
  • Neovascularization is a complex biological process involving numerous cellular and molecular components.
  • Patients with refractory angina and peripheral artery disease are potential candidates for angiogenesis therapies.

Purpose of the Study:

  • To review the clinical development of basic fibroblast growth factor (FGF-2) for therapeutic angiogenesis.
  • To evaluate the efficacy and safety of FGF-2 in human trials for cardiovascular conditions.
  • To outline optimal clinical trial designs for advancing FGF-2 therapy.

Main Methods:

  • Review of six human clinical trials investigating FGF-2 monotherapy.

Related Experiment Videos

  • Analysis of trial outcomes in patients with coronary artery disease and peripheral artery disease.
  • Assessment of safety and efficacy data from randomized phase II trials.

    • Main Results:

    • FGF-2 therapy has demonstrated provisional safety across multiple trials.
    • Two trials provided proof of concept for therapeutic angiogenesis strategy.
    • Efficacy results were mixed, with one trial showing no significant benefit in coronary artery disease and another showing limited benefit in peripheral artery disease.

    Conclusions:

    • Basic fibroblast growth factor (FGF-2) shows potential for therapeutic angiogenesis but requires further investigation.
    • Clinical trial design is critical for demonstrating FGF-2 efficacy.
    • Optimized trial strategies are needed to advance FGF-2 for cardiovascular disease treatment.